Table II.
Anti-SARS–CoV-2 IgG levels in serum and FF.
| IgG presence | Vaccine | COVID | Control | Total | ||
|---|---|---|---|---|---|---|
| Number | 9 | 9 | 14 | 32 | P-value | |
| Serum | Positive | 7 | 8 | 0 | 15 | <0.001 |
| Negative | 2 | 1 | 14 | 17 | ||
| Positive | 77.8% | 88.9% | 0% | 53.1% | ||
| IgG* mean | 4877.4 | 351.2 | 0 | 0.096 | ||
| IgG SD | 7219 | 333.3 | 0 | |||
| FF | Positive | 7 | 8 | 0 | 15 | <0.001 |
| Negative | 2 | 1 | 14 | 17 | ||
| Positive | 77.8% | 88.9% | 0% | 53.1% | ||
| IgG mean | 3720.6 | 266.8 | 0 | 0.1256 | ||
| IgG SD | 6038.8 | 242.8 | 0 | |||
| Ratio FF/serum | Mean ± SD | 0.62 ± 0.21 | 0.79 ± 0.08 | N/A | 0.0665 |
The presence of IgG was analyzed with Chi-square and its quantity with univariate ANOVA.
*
Arbitrary units/ml.
SARS–CoV-2, severe acute respiratory syndrome Coronavirus 2; FF, follicular fluid.